This is an excerpt from Second Opinion, a weekly roundup of eclectic and under-the-radar health and medical science news emailed to subscribers every Saturday morning. If you haven't subscribed yet, ...
The biotech company behind the Western world's first gene therapy and the most expensive prescription medicine in history is giving up on the product because of lack of demand. Only one patient has ...
NEW YORK, July 18, 2018 /PRNewswire/ -- Gene Therapies: A Growing Pipeline and Approval of CAR-T Cell Therapies Reflect Increasing Commercial Appeal, Despite Difficulties Faced by products such as ...
-- Marketing Authorization for Glybera ® to Expire on October 25, 2017 -- -- Company Maintains Focus on Core Programs in Hemophilia B, Huntington’s Disease and Congestive Heart Failure -- LEXINGTON, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback